Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/1692
Title: Indications and pitfalls of immunohistochemistry in head and neck cancer
Authors: CALY, Decio de NataleVIANA, AckleiRAPOPORT, AbraoDEDIVITIS, Rogerio AparecidoCURIONI, Otavio AlbertoCERNEA, Claudio RobertoBRANDAO, Lenine Garcia
Citation: BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY, v.79, n.1, p.75-81, 2013
Abstract: Immunohistochemistry (IHC) has been employed in the differential diagnosis of tumors. Objective: To assess the use of IHC in cases of head and neck tumor. Method: This is a retrospective study of the cases included in the Cancer Registry of the institution. Results: IHC was used in 76 (11%) of 704 pathology tests. Most cases were carcinomas (85.80%), and 83.66% of them were squamous cell carcinomas. All tests were done with diagnostic purposes. The most frequently used antibodies were 34BE12 (37.18%), AE1/AE3 (35.9%), 35BH11 (28.21%), CD45 (25.64%), CD20 (24.36V, CD30 (24.36%), CK7 (23.08%) and CD3 (23.08%). Conclusions: IHC was used in 10.67% of the head and neck tumor cases submitted to pathology testing, mostly for carcinoma (5.26%). In the determination of squamous cell carcinoma, IHC accounted for 18.42% of all tumors.

O estudo imunoistoquímico tem sido empregado para a avaliação do diagnóstico diferencial de neoplasia. OBJETIVO: Avaliar o uso do método nos casos de câncer de cabeça e pescoço. MÉTODO: Estudo retrospectivo de casos do Registro Hospitalar de Câncer da instituição. RESULTADOS: De 704 resultados anatomopatológicos, a imunoistoquímica foi realizada em 76 (11%). A maioria correspondeu a carcinomas - 85,80% e, destes, 83,66% eram epidermoides. Todos os exames foram para fins diagnósticos. Houve maior frequência para o uso de 34BE12 (37,18%), AE1/AE3 (35,90%), 35BH11 (28,21%), CD45 (25,64%), CD20 (24,36%), CD30 (24,36%), CK7 (23,08%) e CD3 (23,08%). CONCLUSÃO: A imunoistoquímica foi usada em 10,67% dos casos de câncer de cabeça e pescoço submetidos a exame anatomopatológico, sendo maior para os carcinomas -- 5,26%. Na determinação do carcinoma epidermoide, seu uso foi de 18,42% do total de neoplasias.
Appears in Collections:Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/28

Files in This Item:
File Description SizeFormat 
art_CALY_Indications_and_pitfalls_of_immunohistochemistry_in_head_and_2013_eng.PDFpublishedVersion (English)168.7 kBAdobe PDFThumbnail
View/Open
art_CALY_Indications_and_pitfalls_of_immunohistochemistry_in_head_and_2013_por.PDFpublishedVersion (Portuguese)200.06 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.